Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

摘要

STUDY QUESTION What is the cost effectiveness of vaccination with the seven valent, 10 valent, and 13 valent pneumococcal conjugated vaccines (PCV-7, PCV-10, and PCV-13) within the Dutch national immunisation programme? SUMMARY ANSWER Under base case assumptions, the incremental cost effectiveness ratio of the current Dutch infant vaccination programme with PCV-7 was estimated at 113891 (?300; dollar145000) per quality adjusted life year (QALY), compared with 52947 and 50042 perQALYfor PCV-10 and PCV-13, respectively.WHAT IS KNOWN AND WHATTHIS PAPER ADDS Recent pneumococcal surveillance studies show a significant increase in non-vaccine serotype disease in immunised populations, which reduces the overall direct effects of vaccination and offsets potential positive herd protection benefits in unvaccinated individuals. Vaccination with PCV-7 was estimated to be not cost effective, whereas the cost effectiveness ratios for PCV-10 and PCV-13 may possibly be acceptable, in particular if total programme costs can be lowered by reduced schedules, reductions in vaccine prices, or both.